Tutorials
Trevi Therapeutics Inc logo

Trevi Therapeutics Inc

$ 3.91 +0.28 (+7.71%) 10:08 PM EST
P/E:
At Loss
P/B:
11.50
Market Cap:
$ 151.26M
Enterprise V:
$ 136.33M
Volume:
287.00K
Avg Vol (2M):
2.03M
Volume:
287.00K
Market Cap $:
151.26M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.03M
Enterprise Value $:
136.33M
PB Ratio:
11.50
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Trevi Therapeutics Inc
NAICS : 325412 SIC : 2834
195 Church Street, 14th Floor, New Haven, CT, USA, 06510
Description
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. It is involved in developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, and levodopa-induced dyskinesia, or LID, in patients with Parkinson's disease.
Name Current Vs Industry Vs History
Cash-To-Debt 2.05
Equity-to-Asset 0.34
Debt-to-Equity 1.36
Debt-to-EBITDA -0.45
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 14.4
3-Year EPS without NRI Growth Rate 10.2
3-Year FCF Growth Rate 14.9
Name Current Vs Industry Vs History
5-Day RSI 75.76
9-Day RSI 65.76
14-Day RSI 62.69
6-1 Month Momentum % 438.71
12-1 Month Momentum % 67.84

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.32
Quick Ratio 2.32
Cash Ratio 2.26

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -17.1
Name Current Vs Industry Vs History
ROE % -204.74
ROA % -90.15
ROIC % -550.57
ROC (Joel Greenblatt) % -14184.85
ROCE % -118.98

Financials (Next Earnings Date:2022-08-12 Est.)

TRVI's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:TRVI

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -1.31
Beta 0.37
Volatility % 254.38
14-Day RSI 62.69
14-Day ATR ($) 0.32871
20-Day SMA ($) 3.513
12-1 Month Momentum % 67.84
52-Week Range ($) 0.46 - 4.09
Shares Outstanding (Mil) 38.69

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Trevi Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More